The PBD Biotech international management team brings together expertise in diagnostics, clinical and veterinary science, disease management and policy.
PBD Biotech Limited specialises in the use of novel phage-based technology for the detection of tuberculosis and related mycobacterial diseases in the fields of human and veterinary diagnostics.
The company has developed proprietary technology that can be used to detect the presence of mycobacteria such as: Mycobacterium tuberculosis (Human TB), second only to Covid as a fatal infectious disease; Mycobacterium (bovine TB) and Mycobacterium avium subsp. paratuberculosis (MAP; Johne’s disease), which are both significant causes of loss of profitability in the agricultural industry.
The company was co-founded in 2018, by: Prof. Cath Rees, Professor in Microbiology at the University of Nottingham and Chief Scientific Officer at PBD Biotech; Dr Ben Swift, Research Fellow in Antimicrobial Resistance, Royal Veterinary College and Director of Research and Development at PBD Biotech; together with serial entrepreneur Dr Berwyn Clarke.
The registered office is at Ingenuity Centre, University of Nottingham, UK.
Registered Company Address
Ingenuity Centre,
University of Nottingham,
Innovation Park, Triumph Rd,
Nottingham NG7 2TU,
United Kingdom
Big shout out to all the amazing dairy farmers, together we can eradicate Johne's Disease and the heartbreak that goes with it. #farm24 #agritech @FarmersGuardian @Morrisons https://t.co/f2A1hVLXlj
Read MoreRT @Jamesrgurney: I’m officially looking to hire some folks! Interested in working on phage coevolution and phage therapy? Hiring grad stud…
Read More“Good diagnostics and a vaccine could prevent 26.5 million human #tuberculosis cases over 8 years, according to Global Plan to End TB" - Mondana Cook is our new Chief Operating Officer, helping us develop rapid molecular #TB #diagnostic. #EndTB @StopTB
Read More